Evidence map›Paper›PMID 41203870›Full record

ArticleBiotechnology letters2025

Coloring target and off-target effects of genetically modified nucleases by blue & white colony assays.

Xumeng Chen, Li Xiao, Qian Wang, Lin Zhou, Yingying Xu, Cuilan Zhou, Minhui Dai, Fengjiao Wang, Huifen Xu, Dixian Luo and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xumeng Chen *National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Hunan University of Chinese Medicine, Changsha, 410208, China.
Li Xiao *Laboratory of Molecular Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Qian WangLaboratory of Molecular Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Lin ZhouLaboratory of Molecular Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Yingying XuLaboratory of Molecular Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Cuilan ZhouDepartment of Human Anatomy, University of South China, Hengyang, 421001, China.
Minhui DaiDepartment of Clinical Dietitian, Xiangya Hospital, Central South University, Changsha, 410008, China.
Fengjiao WangLaboratory of Molecular Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Huifen XuDepartment of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310057, China.
Dixian LuoDepartment of Laboratory Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Guangdong, 518000, China.
Pierre SiroisNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Hunan University of Chinese Medicine, Changsha, 410208, China.
Kai LiNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Hunan University of Chinese Medicine, Changsha, 410208, China.
Duanfang LiaoNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Hunan University of Chinese Medicine, Changsha, 410208, China. dfliao@hnucm.edu.cn.ORCID http://orcid.org/0000-0002-4571-3704
Jia ZhangNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Hunan University of Chinese Medicine, Changsha, 410208, China. jia34@yahoo.com.

Funding

Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul NS2021016Program of Clinical Research Center of Neurological Disease ND2022B04the Suzhou Science and Technology Planning Project SKY2021047
6 · The paper itself

Abstract

More sensitive evaluation of the off-target effects of gene editing nucleases is crucial for human gene therapy. Here we report chromogenic assays designed for sensitive evaluation of gene editing activities using CRISPR/Cas9 test system. Based on beta-galactosidase alpha complementation, qualitative and quantitative evaluations of the target and off-target effects of CRISPR/Cas9 were well established through the color alteration of the E.coli colonies. In addition to target effect analysis, these new assays provide extremely sensitive and efficient tool to profile the off-target effects with one or more bases mismatched between the targets and the gRNAs. Moreover, these assays allow the identification of gene editing effects for off-targets with one base mismatched PAM sites.

Indexed as

CRISPR-Cas SystemsEndonucleasesGene Editingbeta-GalactosidaseEscherichia coliHumansbeta-GalactosidaseEndonucleasesBlue & white assaysCRISPR/Cas9Off-target effectsPAM sites

Identifiers

PMID41203870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.